Jonatan Salzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6800191/publications.pdf

Version: 2024-02-01

43 papers	2,057 citations	394421 19 h-index	276875 41 g-index
43 all docs	43 docs citations	43 times ranked	2513 citing authors

#	Article	IF	Citations
1	Free vitamin <scp>D₃</scp> index and vitamin Dâ€binding protein in multiple sclerosis: A presymptomatic caseâ€“control study. European Journal of Neurology, 2022, 29, 2335-2342.	3.3	5
2	Internet-based vestibular rehabilitation versus standard care after acute onset vertigo: a study protocol for a randomized controlled trial. Trials, 2022, 23, .	1.6	1
3	Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurology, The, 2022, 21, 693-703.	10.2	45
4	Normative video head impulse test data in subjects with and without vascular risk factors. European Archives of Oto-Rhino-Laryngology, 2021, 278, 2619-2624.	1.6	6
5	Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. Multiple Sclerosis Journal, 2021, 27, 1814-1822.	3.0	19
6	Discontinuation and dose reduction of rituximab in relapsingâ€“remitting multiple sclerosis. Journal of Neurology, 2021, 268, 2161-2168.	3.6	21
7	Variability of Normal Pressure Hydrocephalus Imaging Biomarkers with Respect to Section Plane Angulation: How Wrong a Radiologist Can Be?. American Journal of Neuroradiology, 2021, 42, 1201-1207.	2.4	5
8	Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosisâ€”a presymptomatic caseâ€“control study. European Journal of Neurology, 2021, 28, 3072-3079.	3.3	20
9	Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurology, 2020, 77, 184.	9.0	342
10	Radiological markers of idiopathic normal pressure hydrocephalus: Relative comparison of their diagnostic performance. Journal of the Neurological Sciences, 2020, 408, 116581.	0.6	15
11	Prevention of postâ€dural puncture headache: a randomized controlled trial. European Journal of Neurology, 2020, 27, 871-877.	3.3	15
12	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	5.3	86
13	Effectiveness of care in acute dizziness presentations. European Archives of Oto-Rhino-Laryngology, 2019, 276, 2389-2396.	1.6	4
14	Inflammatory activity and vitamin D levels in an MS population treated with rituximab. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731982659.	1.0	11
15	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology, 2019, 26, 1060-1067.	3.3	27
16	Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurology, 2018, 75, 320.	9.0	155
17	Interaction Should Guide Management Decisions. American Journal of Neuroradiology, 2018, 39, E57-E57.	2.4	0
18	Dizziness and the Acute Vestibular Syndrome at the Emergency Department: A Population-Based Descriptive Study. European Neurology, 2018, 79, 5-12.	1.4	28

#	Article	IF	Citations
19	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology, 2016, 79, 950-958.	5.3	190
20	CSF neurofilament light. Neurology, 2016, 87, 1068-1069.	1.1	16
21	Rituximab in multiple sclerosis. Neurology, 2016, 87, 2074-2081.	1.1	278
22	Rituximab in paediatric onset multiple sclerosis: a case series. Journal of Neurology, 2016, 263, 322-326.	3.6	42
23	Vitamin D and axonal injury in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1027-1031.	3.0	39
24	How to minimize the risk for headache? A lumbar puncture practice questionnaire study = Hogyan csÃ¶kkenthetÅ‘ a posztpunkciÃ³s fejfÃ¡jÃ¡s? KÃ©rdÅ‘Ãves vizsgÃ¡lat a lumbÃ¡lpunkciÃ³s gyakorlatrÃ³l. Ideggyogyaszati Szemle, 2016, 69, 397-402.	0.7	2
25	Increasing prevalence of multiple sclerosis in VÃsterbotten County of Sweden. Acta Neurologica Scandinavica, 2015, 132, 389-394.	2.1	16
26	Lumbar puncture preferences among Swedish neurologists. Neurological Research, 2015, 37, 92-94.	1.3	4
27	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level â€“ YES. Multiple Sclerosis Journal, 2015, 21, 1239-1240.	3.0	7
28	Vitamin D and multiple sclerosis-from epidemiology to prevention. Acta Neurologica Scandinavica, 2015, 132, 56-61.	2.1	30
29	MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology, 2014, 83, 2099-2100.	1.1	2
30	Vitamin D and multiple sclerosis: where do we go from here?. Expert Review of Neurotherapeutics, 2014, 14, 9-18.	2.8	19
31	The interaction between smoking and Epstein-Barr virus as multiple sclerosis risk factors may depend on age. Multiple Sclerosis Journal, 2014, 20, 747-750.	3.0	19
32	The trials and tribulations of vitamin D: time for the â€˜sunshineâ€™ vitamin to come in out of the cold â€“ or just more broken promises?. Expert Review of Endocrinology and Metabolism, 2014, 9, 327-344.	2.4	6
33	Maternal vitamin D status during pregnancy and bone-mineral content in offspring. Lancet, The, 2013, 382, 766-767.	13.7	0
34	Epsteinâ€“Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: No. Multiple Sclerosis Journal, 2013, 19, 1692-1693.	3.0	5
35	Smoking as a risk factor for multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1022-1027.	3.0	54
36	Vitamin D and multiple sclerosis: timing of sampling, treatment and prevention. Biomarkers in Medicine, 2013, 7, 193-195.	1.4	4

#	Article	IF	Citations
37	Epstein-Barr virus antibodies and vitamin D in prospective multiple sclerosis biobank samples. Multiple Sclerosis Journal, 2013, 19, 1587-1591.	3.0	49
38	Vitamin A and systemic inflammation as protective factors in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1046-1051.	3.0	28
39	Timing of cigarette smoking as a risk factor for multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 205-205.	3.5	3
40	Vitamin D as a protective factor in multiple sclerosis. Neurology, 2012, 79, 2140-2145.	1.1	192
41	Season of birth and multiple sclerosis in Sweden. Acta Neurologica Scandinavica, 2010, 121, 20-23.	2.1	38
42	Erratum. Acta Neurologica Scandinavica, 2010, 122, 70-73.	2.1	47
43	Neurofilament light as a prognostic marker in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 287-292.	3.0	162